Abstracts tagged "Biomarkers"

Abstract Number: 2189 • 2013 ACR/ARHP Annual Meeting
TLR 4 Endogenous Ligand MRP8/14 Levels in Enthesitis Related Arthritis (ERA) and Its Association With Disease Activity and TLR 4 Expression
Amita Aggarwal¹, Mujeeb Rahman¹, Arpita Myles², Priyanka Gaur² and Ramnath Misra¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Enthesitis related arthritis (ERA) is an inflammatory disease of childhood that lacks autoreactive T and B cells. We have previously shown that surface expressed…
Abstract Number: 1716 • 2013 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus With Clinical Neurocognitive Dysfunction Have Lower Nodal Density and Connectivity On Diffusion Tensor Imaging
Jordan T. Jones¹, Mark DiFrancesco², Ahmad I. Zaal¹, Marisa S. Klein-Gitelman³, Darren Gitelman⁴, Jun Ying⁵ and Hermine Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁴Neurology, Northwestern University, Chicago, IL, ⁵Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH
Background/Purpose: Neurocognitive dysfunction (NCD) is common in childhood-onset systemic lupus erythematosus (cSLE), and often difficult to detect with current resources. Diffusion tensor imaging (DTI) is…
Abstract Number: 879 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers Of Specific Mode Of Action For Early Identification Of Rheumatoid Arthritis Patients Who Respond To Anti-IL6 Or Anti-TNF Treatment
Anne C. Bay-Jensen¹, Natasja Stæhr Gudman², Anne Sofie Siebuhr¹, Claus Christiansen³ and Morten Asser Karsdal², ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized debilitating joint destruction, if not treated aggressively in the patient in most need of treatment. …
Abstract Number: L19 • 2013 ACR/ARHP Annual Meeting
Kellgren-Lawrence Grade (KL) 0 Vs. KL 1 Knees Differ in Their MRI Predictors of Subsequent Radiographic Osteoarthritis
C.Kent Kwoh¹, Ali Guermazi², Tomoko Fujii³, Robert M. Boudreau³, Michael Hannon⁴, Jason Grago⁴, David Hunter⁵, Felix Eckstein⁶ and Frank Roemer⁷, ¹Department of Medicine, The University of Arizona Arthritis Center, Tucson, AZ, ²Radiology, Boston University School of Medicine, Boston, MA, ³Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵University of Sydney, Sydney, Australia, ⁶Paracelsus Medical University, Salzburg, Austria, ⁷Klinikum Augsburg, Augsburg, Germany
Background/Purpose: Kellgren-Lawrence grade (KL) 1, defined by a questionable osteophyte and/or doubtful joint space narrowing, is thought to be an intermediate stage from non-OA (i.e.,…
Abstract Number: 2865 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course
AnneMarie C. Brescia¹, Megan M. Simonds², Suzanne M. McCahan², Paul T. Fawcett² and Carlos D. Rose¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE
Background/Purpose: Our goal is the identification of informative synovial biomarkers to predict persistent vs extended course in oligoarticular JIA patients. Methods: Stored remnant synovial fluid…
Abstract Number: 2071 • 2013 ACR/ARHP Annual Meeting
Adipokines Contribute To The Inflammatory Response In Adult and Juvenile Myositis
Molly S. Hein¹, Cynthia S. Crowson², Helen Khun², Consuelo Lopez de Padilla³, Erik J. Peterson⁴, Emily Baechler⁵ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁴Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁵Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Recently adipokines have been implicated for their role in regulating immune and inflammatory responses in autoimmune disease. To test the hypothesis that adipokines are…
Abstract Number: 1609 • 2013 ACR/ARHP Annual Meeting
AMG 811 (anti-IFN-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL10 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies
David A. Martin¹, Andrew Welcher², Michael Boedigheimer², Zahir Amoura³, Alan Kivitz⁴, Jill P. Buyon⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Alla Rudinskaya⁸, Kevin M. Latinis⁹, S Cohen¹⁰, Cynthia Aranow¹¹, Mike Damore², Winnie Sohn², Kit Chiu², Christine Wang¹², Naren Chirmule², Barbara Sullivan² and James Chung², ¹Medical Sciences, Amgen, Seattle, WA, ²Amgen, Thousand Oaks, CA, ³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Danbury Hospital, Danbury, CT, ⁹Latinis Rheumatology, Leawood, KS, ¹⁰Metroplex Clinical Research Center, Dallas, TX, ¹¹The Feinstein Institute, Manhasset, NY, ¹²Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: Interferon-gamma (IFN-g) is a major pro-inflammatory cytokine that modulates the function of several important populations of immune cells including B cells, T cells, and…
Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Nicolas Wisniacki¹, Chris Stebbins², Jadwiga Bienkowska³, Susan Gawlak², Donald Bennett⁴, Yuhong Xiang⁵, Andrea Dearth⁶, Linda C. Burkly⁷, Ann Ranger⁶, Carrie Wager⁵, Laurence S. Magder⁸ and Michelle Petri⁹, ¹Medical Research, Biogen Idec, Maidenhead, United Kingdom, ²Translational Medicine, Biogen Idec, Cambridge, MA, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biostatistics, Biogen idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec Inc, Cambridge, MA, ⁷Biogen Idec, Cambridge, MA, ⁸Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…
Abstract Number: L13 • 2013 ACR/ARHP Annual Meeting
Serum 14-3-3η Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients
D. van Schaardenburg¹, Marian van Beers-Tas², Karin Britsemmer², Mairead Murphy³, Walter P. Maksymowych⁴, Maarten Boers⁵ and Anthony Marotta⁶, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁶Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The focus of RA management is increasingly towards early detection and treatment. While newly-diagnosed patients will benefit from treatment decisions based on more robust…
Abstract Number: 2805 • 2013 ACR/ARHP Annual Meeting
Synovial Explant Inflammatory Mediator Production Is Associated With Synovitis While Not With Bone Marrow Edema In Rheumatoid Arthritis: A Cross Sectional Study
Martin Andersen¹, Mikael Boesen², Karen Ellegaard¹, Robin Christensen³, Kalle Söderström⁴, Søren Torp-Pedersen¹, Bente Danneskiold-Samsøe¹, Else Marie Bartels⁵, Nina Vendel⁶, Niels H. Søe⁷, Pieter Spee⁸, Ulrik GW Mørch⁹, Lars Karlsson⁴ and Henning Bliddal¹⁰, ¹Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ²Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Department of Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiskberg, Denmark, ³Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ⁴Biopharmaceutical Research Unit, Novo Nordisk, Translational Immunology, Biopharmaceutical Research Unit, Måløv, Novo Nordisk, Denmark, Måløv, Denmark, ⁵Rheumatology, Copenhagen University Hospital,Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ⁶Department of Anaesthesiology, Intensive Care and Operations, Gentofte University Hospital, Denmark, Hellerup, Denmark, ⁷Department of Orthopedics, Section of Hand Surgery, Gentofte University Hospital, Department of Orthopedics, Section of Hand Surgery, Gentofte University Hospital, Denmark, Hellerup, Denmark, ⁸Biopharmaceutical Research Unit Novo Nordisk, Translational Immunology, Biopharmaceutical Research Unit, Måløv, Novo Nordisk, Denmark, Måløv, Denmark, ⁹Biomarkers, Søborg, Novo Nordisk, Denmark, Biomarkers, Søborg, Novo Nordisk, Denmark, Søborg, Denmark, ¹⁰The Parker Institute, Copenhagen, Denmark
Background/Purpose: Synovitis and bone damage may represent two distinct but overlapping pathological processes in rheumatoid arthritis (RA). Whereas the bulk of synovial cells contribute to…
Abstract Number: 2082 • 2013 ACR/ARHP Annual Meeting
Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy
Consuelo Lopez de Padilla¹, Cynthia S. Crowson², Molly S. Hein³, Helen Khun², Rohit Aggarwal⁴, Marc C. Levesque⁵, Dana P. Ascherman⁶, Chester V. Oddis⁷ and Ann M. Reed³, ¹Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Serum cytokines play an important role in the pathogenesis of myositis by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of…
Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Kyriakos A. Kirou¹, Mikhail Olferiev¹, Elzbieta E. Jacek¹, Mari Lliguicota¹, Margaret Robotham¹, Wei-Ti Huang², Elena Gkrouzman¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…
Abstract Number: 813 • 2013 ACR/ARHP Annual Meeting
Citrulline Specific CD4+ T Cells Exhibit a Th1 Memory Phenotype In Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy
Eddie James¹, Mary Rieck², Jennifer Pieper³, John Gebe⁴, Betty Yue⁴, Megan Tatum⁵, Charlotta Sandin⁶, Lars Klareskog⁷, Vivianne Malmström⁸ and Jane Buckner⁹, ¹Benaroya Research Institute, Seattle, WA, ²Translational Research Program, Benaroya Research Institute, Seattle, WA, ³Department of Medicine, Karolinska Institutet, Rheumatology Unit, Stockholm, Sweden, ⁴Diabetes Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA,, Seattle, WA
Background/Purpose: Rheumatoid arthritis is thought to be a T cell mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to…
Abstract Number: 2756 • 2013 ACR/ARHP Annual Meeting
Serum Periostin Is Associated With Prevalent Knee Osteoarthritis and Predicts Disease Progression In Women: The Ofely Study
Jean-Charles Rousseau¹, Elisabeth Sornay-Rendu¹, Cindy Bertholon¹, Patrick Garnero² and Roland Chapurlat³, ¹INSERM UMR 1033, Lyon, France, ²INSERM, UMR 1033, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, ³Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France
Background/Purpose: Periostin (POSTN) is a secreted vitamin K-dependent (Gla-containing) protein produced by osteoblasts and chondrocytes. The aim of this study was to investigate the relationships…
Abstract Number: 2057 • 2013 ACR/ARHP Annual Meeting
Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Ann M. Reed¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla³, Helen Khun², Rohit Aggarwal⁴, Dana P. Ascherman⁵, Marc C. Levesque⁶ and Chester V. Oddis⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The aim of this study was to examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as biomarkers of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].